MedTrace Logo

No-Reflow in Patients With STEMI After Intracoronary Tirofiban After Opening of the Track

NCT06966674 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-05-13

No results posted yet for this study

Summary

This study aims to assess the no-reflow in patients with STEMI after intracoronary glycoprotein IIb/IIIa inhibitors after opening of track in thrombus.

Conditions

  • No-Reflow
  • STEMI
  • Intracoronary
  • Tirofiban

Interventions

DRUG

Intracoronary tirofiban

Patients will receive intracoronary tirofiban (Aggrastat®) (25 mg/kg).

DRUG

Saline 0.9%

Patients will receive intracoronary saline 0.9% solution as a control group.

Sponsors & Collaborators

  • Kafrelsheikh University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-12
Primary Completion
2025-10-01
Completion
2025-10-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06966674 on ClinicalTrials.gov